Nephroprotective value of N-acetylcysteine for patients with concomitant trauma, as well as other aspects of the use of this drug in clinical practice

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

An analysis and review of domestic and foreign literature on the role of N-acetylcysteine in the correction of oxidative stress, as well as the problem of oxidative stress, and protection against free radicals are presented in the article. The important role of N-acetylcysteine in replenishing the intracellular glutathione level, which is the main cell antioxidant, has been shown, as well as the potential use of N-acetylcysteine for various pathological conditions and diseases. The relevance of concomitant injury and renal dysfunction, and the experience of the clinical use of N-acetylcysteine as a nephroprotector in patients with concomitant injury in the clinic of the Department of Faculty and Endoscopic Surgery of KBSU named after Kh.M. Berbekov are also described. After reviewing the literature, based on the results of many experimental studies, we can conclude that this pharmacological substance is a very promising for replenishing the intracellular glutathione pool, and it becomes possible to include it in the combined therapy of a number of human diseases.

Texto integral

Acesso é fechado

Sobre autores

I. Miziev

Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Autor responsável pela correspondência
Email: kfeh@yandex.ru

Ph.D., MD, professor, director of the medical academy, Head of the Department of Faculty and Endoscopic Surgery of Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Rússia, Nalchik

M. Makhov

Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Email: mahov_murat@mail.ru

Ph.D., urologist, assistant professor at the Department of Faculty and Endoscopic Surgery of Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Rússia, Nalchik

A. Makhova

Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Email: alinose77@gmail.com

clinical resident of the 1st year of study in the field of training “Nephrology” of the Federal State Budgetary Educational Institution of Higher Education “Kabardino-Balkarian State University named after H.M. Berbekov"

Rússia, Nalchik

L. Shiritova

Federal State Budgetary Educational Institution of Higher Education «Kabardino-Balkarian State University named after H.M. Berbekov»

Email: asin07@mail.ru

6th year student at the Medical Academy in the direction of “General Medicine”, Federal State Budgetary Educational Institution of Higher Education “Kabardino-Balkarian State University named after. HM. Berbekova"

Rússia, Nalchik

L. Gubzhokova

Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation

Email: alinose77@gmail.com

5th year student in the direction of “General Medicine”, Federal State Autonomous Educational Institution of Higher Education «Russian National Research Medical University named after N.I. Pirogov» Ministry of Health of the Russian Federation

Rússia, Moscow

Bibliografia

  1. Miziev I.A., Makhov M.Kh. Investigation of serum cysteine concentration to monitor glomerular filtration rate for early diagnosis of acute kidney injury in patients with combined trauma. Urologiia. 2017;5:48–51. DOI: https://dx.doi.org/10.18565/urology.2017.5.48–51. Russian (Мизиев И.А., Махов М.Х. Исследование сывороточной концентрации цистатина С для мониторинга скорости клубочковой фильтрации с целью ранней диагностики острого повреждения почек у больных с сочетанной травмой. Урология. 2017;5:48–51. DOI: https://dx.doi.org/10.18565/urology.2017.5.48–51).
  2. Miziev I.A., Makhov M.H. Diagnosis of acute kidney injury in the early stages of treatment of victims of combined trauma using a high-precision biomarker cystatin S. Materials of the VII All-Russian Conference of students, postgraduates and young scientists «Promising innovative projects of young scientists». Nalchik 2017. Р. 171–174. Russian (Мизиев И.А., Махов М.Х. Диагностика острого повреждения почек на ранних этапах лечения пострадавших от сочетанной травмы с помощью высокоточного биомаркера цистатина С. Материалы VII Всероссийской конференции студентов, аспирантов и молодых ученых «Перспективные инновационные проекты молодых ученых». Нальчик, 2017. С. 171–174).
  3. Miziev I.A., Makhov M.H. Cystatin C in the early diagnosis of acute renal failure in patients with concomitant trauma. Bulletin of the Russian Academy of Natural Sciences. 2018 г. Р. 51–55. Russian (Мизиев И.А., Махов М.Х. Цистатин С в ранней диагностике острой почечной недостаточности у больных с сочетанной травмой. Вестник Российской академии естественных наук. 2018. С. 51–55).
  4. Nita M., Grzybowski A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxid Med Cell Longev. 2016;2016:3164734. doi: 10.1155/2016/3164734.
  5. Ung L. et al. Oxidative stress and reactive oxygen species: a review of their role in ocular disease. Clinical Sci. 2017;131(4):2865–2883. doi: 10.1042/CS20171246.
  6. Yadav U.C., Kalariya N.M., Ramana K.V. Emerging role of antioxidants in the protection of uveitis complications. Curr Med Chem. 2011;18(6):931–942. doi: 10.2174/092986711794927694.
  7. Kumar N. Rajendran et al. The Influence of Light on Reactive Oxygen Species and NF-кB in Disease Progression. Antioxidants (Basel). 2019;8(640):1–16. doi: 10.3390/antiox8120640.
  8. Chatterjee S. Oxidative Stress, Inflammation, and Disease. Oxidative stress and biomaterials / ed.: T. Dziubla, D. A. Butterfield. London, 2016. Ch. 2. P. 35–58. doi: 10.1016/b978-0-12-803269-5.00002-4.
  9. Pavarino E.C. et al. Glutathione: Biosynthesis and Mechanism of Action. Glutathione. Biochemistry, mechanisms of action and biotechnological implications / ed.: N. Labrou, E. Flemetakis. New-York, 2013. Ch. 1. P. 1–34.
  10. Zenkov N.K., Kolpakov A.R., Menshchikova E.B. The redox-sensitive Keap1/Nrf2/ARE system as a pharmacological target in cardiovascular pathology. Siberian Scientific Medical Journal. 2015;35(5):5–25. Russian (Зенков Н.К., Колпаков А.Р., Меньщикова Е.Б. Редокс-чувствительная система Keap1/Nrf2/ARE как фармакологическая мишень при сердечно-сосудистой патологии. Сибирский научный медицинский журнал. 2015;35(5):5–25).
  11. Bachhawat A.K., Yadav S. The glutathione cycle: Glutathione metabolism beyond the γ-glutamyl cycle. IUBMB Life. 2018;70(7):585–592. doi: 10.1002/iub.1756.
  12. Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159. doi: 10.1016/j.pharmthera.2013.09.006.
  13. Samuni Y. et al. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117–4129. DOI: 10.1016/j. bbagen.2013.04.016.
  14. Atkuri K.R. et al. N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355–339. doi: 10.1016/j.coph.2007.04.005.
  15. Wu F. et al. Glutathione metabolism and its implications for health. J. Nutr. 2004;134(4):489–492. doi: 10.1093/jn/134.3.489.
  16. Cacciatore I. et al. Prodrug approach for increasing cellular glutathione levels. Molecules. 2010;15(3):1242–1264. doi: 10.3390/molecules15031242.
  17. Raghu G. et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19(8):1202–1224. doi: 10.2174/1570159x19 666201230144109.
  18. Tenório M.C.D.S. et al. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel). 2021;10(6):967. doi: 10.3390/antiox10060967.
  19. Radtke K.K. et al. Interaction of N-acetylcysteine and cysteine in human plasma. J Pharm Sci. 2012;101(12):4653–4659. doi: 10.1002/jps.23325.
  20. Zhou J. et al Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. J Pharm Sci. 2015;104(8):2619–2626. doi: 10.1002/jps.24482.
  21. Shi Z., Puyo C.A. N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther Clin Risk Manag. 2020;16:1047–1055. DOI: 10.2147/ TCRM.S273700.
  22. Машковский М.Д. Лекарственные средства. 16-е изд. Москва: Новая волна, 2020. 1216 с.
  23. Akca T. et al. The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage. J Surg Res. 2005;129(1):38–45. DOI: 10.1016/j. jss.2005.05.026.
  24. Aldini G. et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52(7):751–762. doi: 10.1080/10715762.2018.1468564.
  25. Jiao Y. et al. N-acetyl cysteine depletes reactive oxygen species and prevents dental monomer-induced intrinsic mitochondrial apoptosis in vitro in human dental pulp cells. PLoS One. 2011;11(1):Art.e0147858. doi: 10.1371/journal.pone.0147858.
  26. Szeto H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 2006;8(3):E521–E531. DOI: 10.1208/ aapsj080362.
  27. Go Y.M., Chandler J.D., Jones D.P. The cysteine proteome. Free Radic. Biol. Med. 2015;84:227–245. doi: 10.1016/j.freeradbiomed.2015.03.022.
  28. Wardyn J.D., Ponsford A.H., Sanderson C.M. Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans. 2015;43(4):621–626. doi: 10.1042/BST20150014.
  29. Fratta Pasini A.M. et al. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants (Basel). 2021;10(2):Art.272. doi: 10.3390/antiox10020272.
  30. Saddadi F. et al. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2014;25(1):66–72. doi: 10.4103/1319-2442.124489.
  31. Ibrahim H. et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020;219:Art. 108544. doi: 10.1016/j.clim.2020.108544.
  32. AlMatar M., Batool T., Makky E.A. Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects. Curr Drug Metab. 2016;17(2):156–67. doi: 10.2174/1389200217666151210124713
  33. Pei Y. et al. Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects. Oxid Med Cell Longev. 2018;2018:Art. 2835787. doi: 10.1155/2018/2835787.
  34. Nascimento M.M. et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int. 2010;30(3):336–342. doi: 10.3747/pdi.2009.00073.
  35. Decramer M., Rutten-van Mzlken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled Trial. Lancet. 2005;365:1552–1560.
  36. Demedts M., Behr J. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Eng. J. Med. 2005;353:2229–2242.
  37. Feldman L., Efrati S. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007;72(3):359–363. doi: 10.1038/sj.ki.5002295.
  38. Fiorentini С., Falzano L., Rivabene R., Fabbri A., Malorni W. N-acetylcysteine protects epithelial cells against the oxidative imbalance due со Clostridium difficile toxins. FEBS Lett. 1999;453(1–2):124–128.
  39. Grandijean E.M., Berthet P. et al. Efficasy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published duble-blind, placebo controlled clinical trials. Clin. Ther. 2000;22:209–221.
  40. Regueira F.M. et al. Ischemic damage prevention by Acetylcysteine treatment of the donor before orthotopic liver transplant. Transplantation Proceedings. 1997;29:3347–3349.
  41. Stey C. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review // Eur. Respir. J. 2000;16:253.
  42. Van Zandwijk N., Dalesio О., Pastorino U. et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Natl. Cancer Inst. 2000;92:977–986.
  43. Zheng С.Н., Ahmed К., Rikicomi N., Marrinez G., Nagaiake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol. Immunol. 1999;43(2):107–113.
  44. Павлов В.Н., Пушкарев А.М., Кондратенко Я.В., Сафиуллин Р.И., Алексеев А.В.. Маркеры повреждения почек и нефропротективная терапия при радикальной цистэктомии. Урология. 2015;5:27–30.
  45. Schwalfenberg, G.K. N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab. 2021;2021:Art. 9949453. doi: 10.1155/2021/9949453.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2024